Try our Advanced Search for more refined results
Life Sciences - May, 2020
369 articles
- Mylan Gets More Sanofi Insulin Pen Patents Nixed At PTAB
- FDA Seeks Orange Book Feedback As Drug Guide Turns 40
- Dems Ask Pentagon How It's Spending $10.6B In Virus Funds
- Cannabis Bill Roundup: La. May Expand Medical Pot Access
- COVID-19 IP Catch-Up: Remdesivir Access, Zoom TM Security
- COVID-19 Securities Catch-Up: The 8 Biggest Investor Actions
- AdventHealth Sues Attorney Over Failed $57.5M Masks Deal
- Fed. Circ. Backs PTAB Trim Of Boston Scientific Spine Pain IP
- Fla. Tells State High Court Medical Pot Statute Is Lawful
- Trump Says US Exiting WHO Over COVID-19 Response
- Tax Incentives May Not Spur US Operations In Virus Fight
- Feds Fight Pharmacists' Bid To Ax Opioid Indictment
- Gov't Contracts Of The Month: Virus, Space And Google Deals
- Columbia Care Accused Of Plot To Steal Fla. Pot License
- Avoiding Inadvertent Privilege Waivers In E-Communications
- Incentives And Risks From OTC Drug Monograph Revamp
- Medical Tech Co. Looks To Dodge Investor Suit Over Backlog
- 5 Tips For Drafting Effective Legal Billing Guidelines
- Pharma Suppliers Appeal CMA Action Over UK Market Rig
- Pet Products Maker Accused of Monopolizing Online Market
- IP Owners Approach USPTO Evidence Proposal With Caution
- Assessing The Novel Antitrust Claims In Humira Case
- Lye Makers Want Out Of National Consolidated Antitrust Suit
- 10th Circ. Revives Genentech Cancer Drug Dosage Suit
- PTAB Takes Up 1 Of 2 Gilead Challenges To State Univ. Patent
- 3 Firms Steer Oncology Biotech's $350M Spinoff, IPO Plans
- Ex-USPTO Head, Retired Judge Back China Pharma IP Reform
- Express Scripts Loses Bid To Probe Emails In Antitrust Case
- Pediatric Home Care Giant Aveanna Hit With Data Breach Suit
- DOJ Says BigLaw Firms Put FBI Agent At Risk Of COVID-19
- Pharma Cos. Slam Cert. Bid In Diabetes Drug Price-Fixing Suit
- NJ Court Challenged Over Prolonged Sealing Of FCA Cases
- 2 Accused PED Suppliers Deny Horse Doping Charges
- Investor Sues Qiagen To Block $11.5B Thermo Fisher Deal
- FDA Asks Full DC Circ. To Undo Eagle's Orphan Drug Win
- Indian Generic Pharma Co. Can't Get $500M Award Nixed
- Don't Cancel Your Summer Associate Programs
- Tech Will Play Key Role In Real Estate's Road To Recovery
- Avoiding M&A Deal-Breaking Disputes During A Downturn
- Early Securities Litigation Trends Stemming From Recent IPOs
- Dems Press Pompeo For Info On Russian Ventilator Purchase
- EU Waives Fix For Takeda's £46B Shire Deal
- Gibson Dunn Guides Gene Test Co.'s IPO Amid COVID Slump
- Bipartisan Bill Proposes $100B In New Tech Funding
- Activists Say Gov't Should Have Rights To Remdesivir Patents
- Nonprofit Battelle Says Ex-Employee's FCA Suit Is Hollow
- Investors Say AmerisourceBergen Knew About Drug Scheme
- Ark. Harvest Health Affiliate Must Drop Name Amid TM Row
- La-Roche Can't Shake Class Cert. In Environmental Suit
- Car Ruling Bolsters Dicamba Punitive Damages, Farm Says
- Biotech Working On COVID-19 Therapies Raises $105M
- Ohio Counties Hit Pharmacies With Opioid Nuisance Claims
- Dispensary Tells 9th Circ. Pot Biz Tax Law Is Unconstitutional
- Sorrento Sued Over COVID-19 'Cure' Comment To Fox News
- 5 Ways To Reduce Post-Pandemic Legal Malpractice Exposure
- Sanofi To Raise $11.1B In Sale Of Regeneron Stake
- Biotech Pursuing COVID-19 Vaccine Inks $167M Acquisition
- Leaving The Tort System Behind Via Corporate Risk Transfer
- Trade Groups Join Chamber's Push For Virus Liability Shield
- Gilead Forges $375M 10-Year Partnership With Biopharma Co.
- Taiwan Antitrust Agency Clears Mylan, Pfizer Unit Deal
- $750M Namenda Deal OK'd But 21% Atty Fee Request In Doubt
- Pfizer, Mylan Can't Quickly Appeal EpiPen RICO Class Cert.
- 3 Highlights As HHS Watchdog Voices Concern On Meddling
- Full Fed. Circ. Asked To Abolish Assignor Estoppel Rule
- Drug Cos. Seek To Exit Chicago Opioid Case
- DNA Engineering Co. Codexis Sues Rival For TM Infringement
- Haynes And Boone To Open Office In San Francisco
- Health-Focused Firms Flood IPO Market With Fresh Filings
- Accused PPE Fraudsters Deny NY Price-Gouging Charges
- Immigrant Doctor Says Merck Can't Nix Suit Over Revoked Job
- High Court Won't Review GE, Teva Patent Appeals
- A Guide To Evaluating And Advertising COVID-19 Products
- Credibility Concerns About Virtual Arbitration Are Unfounded
- Shkreli, Vyera Look To Duck Monopolization Claims
- Suit Over 'Illegal' CBD Products Paused To Await FDA Rules
- Coronavirus Regulations: A State-By-State Week In Review
- Goodwin, MoFo Guide Fibrosis Biotech's $90M IPO Plans
- High Court Won't Review Nonconsensual Ch. 11 Releases
- Mallinckrodt Wants More Cuts To Seizure Drug Price Suit
- Medical Co. To Buy Solara, ActivStyle Suppliers For $487M
- Insitro Announces $143 Million Raised In Series B Financing
- Law360 Reveals Titans Of The Plaintiffs Bar
- Amerisource Hid 'Pillbillies' Email In Opioid MDL, Attys Say
- COVID-19 IP Catch-Up: Courts Divided On Getting IP To Trial
- Akorn Gets OK To Tap Into $30M Ch. 11 Funds
- CBD Trade Secret Suit Axed Over Hemp Co.'s Lack Of Counsel
- FDA Approves Hikma's Generic Vascepa Amid Fed. Circ. Fight
- Pfizer, Ranbaxy Sued Over Delay Of Generic Lipitor
- The Current Barriers To International Health Cooperation
- Justices Told Not To Hear Doctrine Of Equivalents Challenge
- FTC Tells 50 More Marketers To Stop Making COVID-19 Claims
- Austrian Manufacturer Wants Out Of Medicare Scheme Suit
- Mintz Bid To Win Malpractice Suit 'Fatally Flawed,' Lab Says
- Surescripts Can't Take FTC Monopoly Case To DC Circ. Yet
- Latham-Led Medical Device Maker Prices Upsized $156M IPO
- The Regulatory Pathway To A Vaccine For COVID-19
- Latham-Led Biopharma Co. Gets $15M For COVID-19 Vaccine
- A Lawyer's Guide To Client Service Continuity Planning
- Increasing Fed. Circ. IPR Appeals Are Shaping Patent Law
- Goodwin Group Combines Life Sciences, Real Estate Attys
- 3 Ways The Pandemic Has Changed How IPOs Are Done
- Michigan Vape Ban Injunction Upheld At Appellate Court
- CBD Co. Issues Recall After FDA Warning Letter
- Chanel Hit With Suit Linking Mesothelioma To Talc Products
- How Pandemic-Related Delays Affect Hatch-Waxman Litigants
- Maximizing Defense Advantages In Jurisdictional Discovery
- Investor Says Elanco Hid Inventory Woes In COVID-19 Bulletin
- Judge Finds Invisalign Maker Can't Dodge Monopoly Claims
- Drug Buyers' Retooled $34M Celgene Deal Wins Initial OK
- Virtual Meetings Could Be Fertile Ground For Legal Discovery
- InfoBionic Asks If Premature Alice Ax Doomed Invalidity Bid
- Former Danaher Exec Dodges Trade Secret, Contract Claims
- Fertility Chain IntegraMed Files For Ch. 7 After $7M Asset Sale
- Akorn Heads Into Ch. 11 For Sale With More Than $1B In Debt
- States Join Bid For Virus Delay In Purdue Pharma Bankruptcy
- Canadian Pot Co. Sundial Escapes NY Securities Suit
- Imerys Slams J&J's Bid To 'Seize Control' Of Its Ch. 11
- 4 Things To Know About Plan To Speed COVID-19 Patent Apps
- Advocacy Groups Decry New Trump Deregulatory Move
- Biopharma Co. Nets $120M To Research Quality Control Tech
- Indicted Generic-Drug Exec Wants Case Tried In New York
- Contingent Fees A Great Option For Cos. During Downturn
- The Role Of Remote Mediation After The Crisis Is Over
- AbbVie Says Recent Antitrust Ruling Irrelevant In Humira Case
- What ITC Means By 'Nexus' In Domestic Industry Test
- Fed. Circ. Urged To End 'Unrealistic' Obviousness Test
- New Info Could Boost Allergan ERISA Suit, 3rd Circ. Told
- NY Judge Won't Require In-Person Testimony In IP Bench Trial
- Compliance Tips For Running Clinical Trials During COVID-19
- US-Based Merck Banned From Using 'Merck' Trademark In UK
- Wachtell-Led Swiss Pharma Co. Raises $340M In Offering
- 7 Steps To Romancing The Virtual Classroom
- Broad, UC Each Tell PTAB It Invented CRISPR First
- US Rebukes Patent, Abortion Language In WHO Resolution
- J&J Unit Must Face Class Claims Over 'Rapid Release' Tylenol
- Imprisoned Pharmacist In No Extra Virus Danger, Feds Say
- Arbitrator Right To Dissolve Pot Partnership Forged In Fraud
- J&J To Stop Talc Sales In North America
- Cannabis Co. Seeks Nix Of Suit Over Scheme To Devalue Rival
- Global Economic Recovery Calls For Trade Policy Overhaul
- Main Street Lending Adjustments Mean Help For More Cos.
- Perceptive Advisors' Blank Check Co. Targets $125M IPO
- Coronavirus Regulations: A State-By-State Week In Review
- 5 Tips For Emergency Relief Petitions During COVID-19
- Key Return-To-Work Considerations For Law Firms
- Biopharma Company Rakes In $145M In Fundraising Effort
- Ropes Leads Cowen Healthcare Investments To $493M Fund
- Mylan Pushes For Mediation In EpiPen Antitrust Suit
- Otsuka Beats Abilify User's Failure-To-Warn Suit In Calif.
- Full Fed. Circ. Skips 1-Line Orders In Apple, Hearing Aid Cases
- 1-800 Contacts To Pay $15M To Exit Consumer Antitrust Case
- Latham-Led Medical Device Maker Inari Launches $110M IPO
- Onshoring Incentives Have Bipartisan Allure In Virus Bill Talks
- J&J Argues For Immunity In $57M Pa. Pelvic Mesh Appeal
- Hong Kong Index To Permit Cos. With Unequal Voting Shares
- German Lab Accused Of Illegally Selling Tick Test Kits In US
- Chancery Sees No Bias Caused By Bouchard In Meso Suit
- 9th Circ. Won't Revive J&J Breast Implant Suit
- A Creative Solution For Teaching Local Practice In Law School
- Bayer Foe Says Emailing Arnold & Porter Counts As Service
- Identifying Antitrust 'Safety Zones' During The Pandemic
- Dr. Reddy's $9M Deal Gets Nod In Quality Control Suit
- Ex-Theranos Exec Wants April 2021 Trial And His Passport
- Supreme Court Still Not Interested In 1-Line Fed. Circ. Orders
- Cell Therapy Company Raises $65M In Funding Round
- Shkreli Release Denied After 'Delusional' Virus Cure Boast
- Pandemic-Bruised IPO Market Shows Signs Of Healing
- Texas Agency Relaxes Guidelines For Controversial Sterilizer
- Europe Authority Bans Patents On Plants And Animals
- HHS Says Gilead Can't Allege Misconduct In HIV Drug IP Suit
- Talc Supplier Imerys Sets Ch. 11 Plan To Resolve Injury Claims
- 3M Settles Price-Gouging Trademark Case In Florida
- Cancer-Focused Biotech's Shares Soar After Upsized IPO
- Supplement Co. Banned From Hawking Fake COVID-19 Cures
- Why Gilstrap Is Getting Ready For Trial — And Not On Zoom
- Bayer, Merck Say Leg Amputation Suit Filed Too Late
- Implied Conflict Preemption May Apply In COVID-19 Cases
- Making Law Firm Panels Work For The Cost-Conscious GC
- How USPTO Examiner Type Affects Patents: Part 1
- #MeToo's Unexpected Implications For Shareholder Litigation
- Ex-Shook Hardy Trial Lawyer Joins Eckert Seamans In Pa.
- 7th Circ. Won't Rethink Allowing National Class In Ill. Fax Suit
- Health Hires: Polsinelli, DLA Piper, Eckert Seamans
- Fed. Circ. Revives Part Of Hearing Aid Patent Challenge
- FDA Warns Of Accuracy Issues With Abbott COVID-19 Tests
- Veeva Slams IQVIA's Sanctions Bid As 'Hyperbolic'
- COVID-19 IP Catch-Up: Source Code Woes, Generic Antivirals
- Pharma Co. Must Face Fraud, Trade Secret Claims In Drug Suit
- Flood Of Medical Funds May Hold Risks For New Contractors
- Sinovac Investor Settles SEC Disclosure Claims For $290K
- Trump Administration Threatens Veto Of Dems' $3T Relief Bill
- FDA Warns Allergan Over Breast Implant Studies
- Conn. Man Ran $2M Liquid Purification Tech Scam, SEC Says
- UCann's CBD Health Claims Must End Ch. 11, Creditor Says
- Tribes Urge Justices To Keep ACA's Indian Health Measures
- Pot Group Urges Legalization To Hike Tax Revenue Amid Virus
- How COVID-19 Is Affecting Drug Supply Regulation
- Voir Dire Tips For Preserving Defense-Friendly Jurors
- Pandemic Presents Teamwork Test For Law Firms
- Trump Moves To Fill Stockpile Ahead Of Next Virus Outbreak
- Highlights From The Virtual Antitrust Spring Meeting: Part 2
- No Bellwether For Diabetics In Insulin Case Despite Virus Risk
- Ex-Vaccine Chief Says Time Running Out For Virus Strategy
- Biogen Thwarts 'Brazen' Drug Copycat With IP Settlement
- Coronavirus Q&A: Arnold & Porter's Chair Of Health, Life Sci
- SEC Targets 2 Cos. Over Misleading COVID-19 Claims
- 1st Circ. Upholds Sanofi's Quick Win Against Age Bias Suit
- NY AG Gets Green Light For Subpoenas Into Sackler Finances
- Don't Bet On Aug. Trial In CVS Drug-Pricing Suit, Judge Says
- Officials Say China Backing Hacks On US Vaccine Research
- CVS Unit To Pay $15M Over 'Improper' Opioid Dispensing
- Natera, Illumina Ink Deal To End Row Over DNA Testing IP
- Judge Slams Andrus Wagstaff's Bid To Dodge Mesh Fee Share
- 9th Circ. Says Calif. Health Exchange Must Face Abortion Suit
- 9 Firms Vie For Lead Counsel In Inovio COVID-19 Vaccine Suit
- Investor Sues Over Nutraceutical's $446M Take-Private Deal
- 8 Tips For Retaining An Expert During COVID-19 And Beyond
- COVID-19 Underscores Diagnostic Patent Eligibility Problems
- 4 Personal Jurisdiction Questions Defendants Should Ask
- MDL Won't Stop PTAB From Reviewing Merck Diabetes Patent
- Monsanto Can't KO Former Worker's Sex Discrimination Suit
- 1-800 Contacts Settles Search Term Class Action
- Gilead Inks Deals With Generic Cos. To Make COVID-19 Drug
- Paul Hastings, Baker Botts Drive $400M Animal Health Deal
- 3 Highlights As Senators Debate Reopenings Amid COVID-19
- Sens. Say Safety Regs Must Precede COVID-19 Biz Immunity
- Merck Aims To Revive Suit Over NJ Town's Zoning Changes
- FEMA Rule Sets New Standards For Priority Medical Contracts
- US Trustee Says Past Pot Biz Enough For Ch. 11 Dismissal
- Veeva Escapes IQVIA's Suit Over Noncompetes
- Zantac Makers Say Drug Has No Cancer Link As MDL Opens
- Conn. Asks Justices To Pass On Drug Price-Fixing Discovery
- Ecolab Accused Of Hiding Health Risks In Its Disinfectants
- What It's Like To Move From Army JAG To BigLaw
- SG Says Due Process Challenge To Retroactive IPRs Fails Too
- Pharma Supply Agreement Considerations During COVID-19
- Expect EPA Scrutiny Of COVID-19 Product Claims
- Coronavirus Regulations: A State-By-State Week In Review
- Lewis Brisbois-Repped Cancer Biotech Plans $25M IPO
- Ex-Worker Says Brandt Finger Scans Violate Ill. Privacy Law
- Real Estate Rumors: Related, Allen & Overy, Welltower
- Arnold & Porter Hires Privacy Pro From Venable
- Activist Investor Elliott Urges Alexion To Consider A Sale
- Actelion Spinoff Loses Bid To Lengthen Patent Term
- Illumina Nears Win In Bid To Block BGI's DNA Product Sales
- Valeant Beats Patent Atty's 'Parasitic' Whistleblower Claims
- COVID Crimes: White Collar Cases To Expect From The Crisis
- Shareholders Say Hemp Co.'s Assets Being 'Robbed' By CEO
- Feds Float Added Charge Against Ex-Theranos CEO
- Prevagen Maker Urges 7th Circ. To Sanction Seller For Appeal
- Goodwin-Led Biotech Pliant Therapeutics Files $86M IPO
- Theranos Offers Defense Lessons For Multi-Agency Probes
- 6th Circ. Opioid Opinion On Federal Rules Helps Cos. In MDLs
- How Law Firms Can Maximize COVID-19 Insurance Coverage
- Younger Attorneys Get Chance At Big Role In Zantac MDL
- The Way Forward For COVID-19 Testing In The US
- Protecting Privilege When Communicating With Contractors
- 4 Firms Steer Cancer-Focused Biotech's $125M IPO Launch
- Missteps To Avoid In Marketing COVID-19 Antibody Tests
- Adapting Information Governance For The COVID-19 Era
- Aetna Sued Over 'Inexplicable' Refusal To Cover Knee Implant
- Shareholders Ink Deal With Ex-Insys Exec Over Fraud Claims
- J&J Must Face Revived Risperdal Labeling Claims In Calif.
- Payors In Ranbaxy MDL Lose 2 State Claims On Notice Rules
- Fed. Circ. Backs Generic Co.'s IP Win Over Eagle Cancer Drug
- AFL-CIO Chief Keeps Up Attack On DOL's Pandemic Response
- COVID-19 IP Catch-Up: USPTO Gets Busy, Zoom Trial Begins
- Fed. Circ. Weighs Scientists' Ties To Cancer Patents
- Pharma Cos. Escape Claims Drugs Caused Painful Disease
- Virtual Caucuses Can Improve The Mediation Process
- Psychedelic Meds Are Opening A New Frontier For Legal Work
- Apotex Seeks To Revive Hospira Unfair Competition Fight
- How To Assess Accounting Materiality Amid Economic Crisis
- USCIS Should Lower Employment Barriers Amid Pandemic
- 3D Printing And The Shifting Legal Landscape For COVID-19
- Coronavirus-Related TM Filings Will Face Registration Hurdles
- Robbins Geller Must Add Atty Names To Lead OvaScience Suit
- Astellas, Indian Generic Cos. Settle IP Fight Over Bladder Drug
- Real Estate Rumors: Sidewalk Labs, Allakos, CalPERS
- Mo. Medical Pot Regulators Want Fight Over Licenses Tossed
- HHS Official Expects Probe Into Ex-Vaccine Chief's Ouster
- Main Street Lending Program Offers Liquidity With Limits
- Tech Giants In Japan Join Free COVID-19 IP Pledge
- Deals Rumor Mill: Lord & Taylor, Walgreens, Warburg Pincus
- Mont. Cannabis Tax Backers To Begin Gathering Signatures
- What All Attorneys Can Learn From Female Rainmakers
- Apotex To Pay $24M Criminal Fine In DOJ Price-Fixing Case
- M&A Ordinary Course Covenants Amid Extraordinary Times
- No Privilege Shield For Firm Consultant, Express Scripts Says
- Cow Breeding Co. Gets Royalty Tweak Years After IP Verdict
- Alexion Nears $25M Settlement With SEC To End FCPA Probe
- Otsuka Nears Win Against Calif. Abilify Failure-To-Warn Suit
- NJ Court Probes Firing Timing In Pharma Whistleblower Suit
- Roche Rails Against Bid To Void Del. Ruling On IP Rights Buy
- Zetia Buyers Blast Merck's 'Unhinged' Bid To Eject Class Rep
- Fla. Defends Medical Pot Regulations Before State High Court
- Fed. Circ. Says Thermo Fisher Can't Call Dibs On Injector IP
- Fed. Circ. Reveals Why It Didn't Revive Boston Scientific IP
- Set Aside Fund For Pandemic Fight, Obama CDC Chief Says
- 4 Takeaways From 3rd Circ. Classwide Antitrust Injury Ruling
- The 1st COVID-19 Prosecutions Under Defense Production Act
- An Early Look At Congressional Oversight Of The Pandemic
- Restasis Buyers Win Cert. Battle In Allergan Monopoly Case
- Female Justices Tear Into Trump's ACA Birth Control Regs
- PTAB Says Articles Doom Part Of Joint Pain Treatment Patent
- Promoting Lawyer Well-Being Is More Essential Than Ever
- Immunology Co. Unveils Platform And $60M In Investments
- Medical Supplier Gets Early OK For $35M Investor Settlement
- AbbVie Gets FTC Clearance For $63B Allergan Buy
- Judge Says Army Tourniquet Dispute Belongs In Claims Court
- New HIV Antitrust Complaint, Same Problems, Gilead Says
- Kirkland & Ellis Poaches Wachtell M&A Partner In NY
- Livent Stock-Drop Suit Driven By Hindsight, Pa. Judge Told
- HHS Official Ousted For Resisting Virus Drug Wants Job Back
- Amgen Comes Out On Top After Bench Trial Over Cancer Drug
- SEC Says Couple Earned $8.5M Trading Off Neighbor's Intel
- Indivior Can Split IP, Antitrust Claims In Suboxone Fight
- 9th Circ. Told It Can't Order Discovery For Private Arbitration
- Manufacturer Can't Claim Hand Sanitizer Stops Diseases
- Bayer Seeks Win In Suit Over Flintstones 'Complete' Vitamins
- An Employer's Guide To COVID-19 Emergency Planning
- Rep. Neal Calls For 90-Day Hold On Medical Product Duties
- Coronavirus Regulations: A State-By-State Week In Review
- Remote Depositions Bring Ethics Considerations For Lawyers
- Coppertone Buyers Read 'Mineral' Label Wrong, Bayer Says
- Rapid Clinical Developments Increase Insider Trading Risks
- Labor Unions May Set Solid Foundation For Cannabis Industry
- Now May Be A Good Time To Rethink Biometric Regulation
- More Reasons To Redesign The Open Office Post-Pandemic
- Paul Weiss, Cooley Drive $1.41B Deal For Portola Pharma
- Ropes Guides Oberland To $1.05B Health Care Royalty Fund
- Conn. High Court Won't Reverse Boehringer Pradaxa Win
- USPTO Unveils Virus Patent Platform, EPO Extends Deadlines
- Perrigo Follows FTC's Wake With AbbVie Testosterone Suit
- Widow Uninjured By Lost Sperm, Calif. Appeals Court Affirms
- FDA Slaps Tighter Controls On COVID-19 Antibody Tests
- 4th Circ. Says Appeal Of E-Cig Compliance Deadline Is Moot
- Gov't Tells Justices Retroactive IPRs Aren't Theft
- Prevagen Buyer Class Decertified After False Ad Suit Mistrial
- Suboxone Buyers Tell 3rd Circ. Case Is Not Like Lamictal
- 3M Wins Its First NY Injunction Over COVID-19 Price-Gouging
- 7 COVID-19 Compliance Areas For Health, Life Sciences Cos.
- Pa. Biotech Cos. Dispute Ownership Of Gene Therapy IP
- J&J Settles W.Va. AG's Pelvic Mesh Claims For $3.9M
- Latham Guides Israeli Biopharma Targeting $50M In US IPO
- Early Pandemic-Related Shifts We're Seeing In Legal Finance
- Celgene Investors Seek Cert. In Suit Over Drug Disclosures
- 3 Firms Steer Menarini's Stemline Deal Worth Up To $677M
- The Death Of The LSAT
- Design Patents Prove Successful On Enforcement, Defense
- EpiPen Buyers Lost Bid To Depose Ex-Teva CEO In MDL
- CDC Urges Meat Plants To Act Quickly To Curb Virus Cases
- FDA Allows Emergency Use Of Gilead Drug For COVID-19
- Genentech Blasts Eli Lilly's $10M Fee Bid For Dropped IP Suit
- Daiichi Told Cancer Drug Patent Fight Must Be Arbitrated
- Mont. Pot Measure Supporters Can't Gather Signatures Online
- Purdue Creditors Get OK For Sackler Bank Subpoenas
- COVID-19 IP Catch-Up: Looming Trials, Jeff Dunham's Dummy
- Taxation With Representation: Weil, White, Kirkland
- DC Circ. Upholds FDA's Abuse-Deterrent Opioid Denial
- Maintaining Product Liability Immunity During The Pandemic
- Sanofi Denies Using Crisis To Obstruct Discovery In Suit
- Dechert's Sheila Birnbaum Talks Remote Work, COVID-19
- 3M Continues Blitz With 4 More Price-Gouging Cases
- Latham Steers As Biotech Firm's $56M IPO Tops Range
- Provisional Patent Applications Are Crucial Amid COVID-19
- Companies Tap Convertible Debt In Droves Amid Pandemic
- Schein Settles Pair Of Investor Suits Over Price-Fixing Claims